Related Experiment Video

Updated: Jun 11, 2026

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Naproxen aggravates doxorubicin-induced cardiomyopathy in rats

Rahila Ahmad Pathan1, Bhulan Kumar Singh, K K Pillai

  • 1Department of Pharmacology, Faculty of Pharmacy, Hamdard University, Hamdard Nagar, New Delhi 110062, India.

Indian Journal of Pharmacology
|July 8, 2010
PubMed
Abstract

Insights

Naproxen (NAP), a nonselective NSAID, was found to be cardiotoxic in rats, worsening doxorubicin-induced cardiomyopathy. This suggests caution when using naproxen in patients with cardiovascular disease.

Area of Science:

  • Cardiology
  • Pharmacology
  • Toxicology

Background:

  • Debate surrounds the cardiovascular safety of nonselective NSAIDs, specifically naproxen (NAP).
  • Previous research highlighted risks associated with NSAIDs, including coxibs and classical agents.
  • The potential cardioprotective effect of naproxen remains controversial.

Purpose of the Study:

  • To investigate the cardiovascular effects of naproxen in a rat model of doxorubicin-induced cardiomyopathy.
  • To assess naproxen's impact on cardiac function and oxidative stress markers.

Main Methods:

  • Male rats received doxorubicin (DOX) to induce cardiomyopathy.
  • Naproxen was administered alone or in combination with DOX and trimetazidine (TMZ).
  • Cardiomyopathy was evaluated using biochemical markers (LDH, TBARS, antioxidant enzymes) and electron microscopy.

Main Results:

  • Doxorubicin significantly increased oxidative stress markers and decreased antioxidant enzyme levels.
  • Naproxen alone demonstrated cardiotoxicity and exacerbated DOX-induced cardiomyopathy.
  • Naproxen abolished the protective effects of trimetazidine against DOX-induced cardiac damage.

Conclusions:

  • Naproxen exhibits cardiotoxic potential and can worsen pre-existing cardiovascular conditions.
  • Cautious use of naproxen is recommended for patients with compromised cardiac function.
  • Further research is warranted to elucidate the cardiovascular risks associated with naproxen.
Keywords:
Apoptosiscardiomyopathyenzyme (kinetics)free radicalsnonsteroidal anti-inflammatory drugs

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...